sarcopenia. Muscle wasting and atrophy, not elsewhere classified
Conditions
Interventions
Intervention 1: The WB-EMS device (manufactured by LT+ Company, Iran) was used in this study. This device includes an electrical pulse generator with 10 output channels. Electrical stimulation was app
Sponsors
Ferdowsi University of Mashhad
Eligibility
Sex/Gender
Male
Age
60 Years to 70 Years
Inclusion criteria
Inclusion criteria: The candidates must be male. The age of the clients must be between 60 and 70 years old. They are affected by sarcopenia.
Exclusion criteria
Exclusion criteria: The candidate has underlying conditions. They have taken hormonal medications and specific supplements. They have had physical activity in the past six months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sarcopenia index. Timepoint: Measurement of sarcopenia index before and after the intervention. Method of measurement: skeletal muscle mass (SMM) by the square of their height (height²). | — |
Secondary
| Measure | Time frame |
|---|---|
| Static balance. Timepoint: Measurement of static balance before and after the intervention. Method of measurement: berg balance scale.;Dynamic balance. Timepoint: Measurement of Dynamic balance before and after the intervention. Method of measurement: The Timed Up and Go (TUG).;Functional capacity. Timepoint: Measurement of Functional capacity before and after the intervention. Method of measurement: The Sitting and Rising Test (SRT).;Muscle mass percentage. Timepoint: Measurement of Muscle mass percentage before and after the intervention. Method of measurement: Body Composition Analysis.;Fat mass percentage. Timepoint: Measurement of Fat mass percentage before and after the intervention. Method of measurement: Body Composition Analysis.;Hand Grip. Timepoint: Measurement of Hand Grip before and after the intervention. Method of measurement: Dynamometer.;Cortisol. Timepoint: Measurement of Cortisol 48 hours before the start of the intervention and 48 hours after the final training session. Method of measurement: Blood Test.;Insulin-like growth factor. Timepoint: Measurement of Insulin-like growth factor, 48 hours before the start of the intervention and 48 hours after the final training session. Method of measurement: Blood Test.;Interleukin 6. Timepoint: Measurement of Interleukin 6, 48 hours before the start of the intervention and 48 hours after the final training session. Method of measurement: Blood Test.;Testosterone. Timepoint: Measurement of Testosterone 48 hours before the start of the intervention and 48 hours after the final training session. Method of measurement: Blood Test.;Tumor Necrosis Factor-alpha (TNF-a). Timepoint: Measurement of Tumor Necrosis Factor-alpha (TNF-a), 48 hours before the start of the intervention and 48 hours after the final training session. Method of measurement: Blood Test.;Follistatin. Timepoint: Measurement of follistatin 48 hours before the start of the intervention and 48 hours after the final training session. Method of mea | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKasra Khayyami
The Ferdowsi University of Mashhad
Outcome results
None listed